A carrier-free nanodrug based on the self-assembly of hydroxysafflor yellow A and ethyl ferulate for cerebral ischemia-reperfusion injury
Source abstract
Abstract
Cerebral ischemia-reperfusion injury (CIRI) primarily manifests through uncontrolled inflammatory reactions and oxidative stress accumulation. Hydroxysafflor yellow A (HYSA), an anti-inflammatory agent commonly used for CIRI treatment, exhibits low bioavailability because of its high water solubility, which necessitates the administration of large doses, leading to adverse side effects. In biomedical engineering, although conventional HYSA-loaded nanocarriers can address the aforementioned issues, they still exhibit several limitations, including carrier-related toxicity, low drug-loading capacity, and various tendencies such as drug crystallization and leakage during storage. To overcome these limitations, we developed carrier-free nanoparticles by covalently linking ethyl ferulate (EF) and HYSA through a reactive oxygen species (ROS)-cleavable oxalyl chloride bridge (HOE). This ROS-responsive design facilitates targeted drug release in ischemic brain regions, thereby synergistically combining the antioxidant properties of EF with the anti-inflammatory effects of HYSA. In vitro studies demonstrated that HOE significantly enhanced ROS-scavenging ability. In CIRI models, HOE markedly reduced cerebral infarct volume and improved neurological recovery compared with HYSA treatment alone, without any observable toxicity. Additionally, HOE codelivered curcumin, further enhancing therapeutic efficacy. By integrating dual therapeutic mechanisms into a self-assembling, excipient-free nanoplatform, HOE effectively overcomes dosage limitations, thereby presenting a synergistic and biocompatible strategy for CIRI treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Curcumin's Biomedical Applications · Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. Acute ischaemic stroke: recent advances in reperfusion treatment10.1093/eurheartj/ehac684 ↗
2. Diagnosis and management of acute ischaemic stroke10.1136/practneurol-2020-002557 ↗
3. Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke: the OPTIMAL-BP randomized clinical trial10.1001/jama.2023.14590 ↗
4. Tenecteplase versus alteplase before thrombectomy for ischemic stroke10.1056/NEJMoa1716405 ↗
5. Current mechanistic concepts in ischemia and reperfusion injury10.1159/000489241 ↗
6. Geum japonicum Thunb. var. Chinese-P.decorata H.Andres herbal pair ameliorates CIRI-induced neuronal injury by facilitating mitochondrial transfer via the CD38/Miro1 signaling pathway10.1016/j.phymed.2026.157928 ↗
7. Structure and function of the blood-brain barrier10.1016/j.nbd.2009.07.030 ↗
8. Stereotactic administration of edaravone ameliorates collagenase-induced intracerebral hemorrhage in rat10.1111/cns.12584 ↗
9. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs10.1002/med.21528 ↗
10. Edaravone for the treatment of amyotrophic lateral sclerosis10.1080/14737175.2019.1581610 ↗
11. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial10.1161/STROKEAHA.120.031197 ↗
12. Erythrocyte membrane camouflaged celastrol and bilirubin self-assembly for rheumatoid arthritis immunotherapy based on STING inhibition and RONS clearance
13. Network pharmacology-based investigation of potential targets of astragalus membranaceous-angelica sinensis compound acting on diabetic nephropathy10.1038/s41598-021-98925-6 ↗
14. Network pharmacology: curing causal mechanisms instead of treating symptoms10.1016/j.tips.2021.11.004 ↗
15. Hydroxysafflor yellow A protects neurons from excitotoxic death through inhibition of NMDARs10.1177/1759091416642345 ↗
16. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs10.1055/s-2005-916249 ↗
17. Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism10.1016/j.phrs.2018.05.012 ↗
18. Ferulic acid and cardiovascular health: therapeutic and preventive potential10.2174/1389557521666210105122841 ↗
19. Antioxidant properties of ferulic acid and its possible application10.1159/000491755 ↗
20. Ethyl ferulate, a lipophilic phenylpropanoid, prevents diabetes-associated renal injury in rats by amelioration of hyperglycemia-induced oxidative stress via activation of nuclear factor erythroid 2-related factor 210.1111/jfbc.13607 ↗
21. Ethyl ferulate protects against lipopolysaccharide-induced acute lung injury by activating AMPK/Nrf2 signaling pathway10.1038/s41401-021-00742-0 ↗
22. Advances in the research of nano delivery systems in ischemic stroke
23. Cerium oxide nanoparticles with antioxidative neurorestoration for ischemic stroke10.1016/j.biomaterials.2022.121904 ↗
24. Carrier-free nanodrug based on Co-Assembly of methylprednisolone dimer and rutin for combined treatment of spinal cord injury10.1021/acsnano.3c00360 ↗
25. Metal-organic framework-edaravone nanoparticles for radiotherapy-induced brain injury treatment10.1016/j.biomaterials.2024.122868 ↗
26. Ligustrazine nanoparticle hitchhiking on neutrophils for enhanced therapy of cerebral ischemia-reperfusion injury
27. "Non-cytotoxic" doses of metal-organic framework nanoparticles increase endothelial permeability by inducing actin reorganization10.1016/j.jcis.2022.12.020 ↗
28. The consequences of particle uptake on immune cells, trends
29. Immune-mediated blood-brain barrier disruption after ischemic stroke: mechanisms and therapeutic targets10.3389/fimmu.2025.1716041 ↗
30. Matrix metalloproteinase-9 in hemorrhagic transformation after acute ischemic strok (Review)10.3892/mmr.2025.13590 ↗
31. Advances in the detection of biomarkers for ischemic stroke10.3389/fneur.2025.1488726 ↗